AEKNIL (Paracetamol) is a drug with antipyretic (fever-reducing) and analgesic (pain-relieving) properties. It has a weak anti-inflammatory action as well.
Paracetamol reduces fever by inhibiting the formation and release of prostaglandins in the central nervous system and inhibiting the action of endogenous pyrogens at the hypothalamic thermoregulatory centers.
The mechanism of analgesic action of Paracetamol is not fully established. Paracetamol may produce analgesia by inhibiting prostaglandin synthesis centrally and elevating the pain threshold.
AEKNIL has been in the market since 1961 and has established itself as a brand of choice and trust among healthcare professionals all over the world. Over the years, AEKNIL has evolved from a single dosage form into multiple product extensions like infusions, tablets, pediatric drops, and syrups to cater to all age groups. All products are manufactured as per cGMP guidelines and have a well-documented safety and efficacy profile.
Numerous clinical trials and pharmacokinetic studies have been performed on AEKNIL range of products over a span of 40 years at multiple sites in India, Middle-East, South-East Asia and Africa.
These trials have confirmed the quality, safety, and efficacy profile of AEKNIL products and have made it a brand of choice and trust among the medical fraternity in India and around the world.
A brief, non-exhaustive list of clinical studies with AEKNIL range of products is given below.